ArticleJournal for immunotherapy of cancer2019
Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
Article in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 32 citations in OpenAlex.
- Single-Dose TACE-Like Injection of Sustained-Release Panobinostat/IL-12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation.Frontiers in immunology · 2026Review
- Increased Peripheral T Stem Cell-like Memory Features in Patients with Advanced Solid Tumors Treated with Tumor-Targeting IL-12 Immunocytokine Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Urinary exosomal lnc-TAF12-2:1 promotes bladder cancer progression through the miR-7847-3p/ASB12 regulatory axis.Genes & diseases · 2025Article
- Immunocytokines in cancer immunotherapy: opportunities and challenges.Frontiers in oncology · 2025Review
- Implications of glycosylation for the development of selected cytokines and their derivatives for medical use.Biotechnology advances · 2024Review
- Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.BMC cancer · 2024Article
- Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.Pharmaceutics · 2024Review
- Interleukin-12 in multimodal tumor therapies for induction of anti-tumor immunity.Discover oncology · 2024Review
- First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.Journal for immunotherapy of cancer · 2023Article
- Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12.International immunopharmacology · 2023Article
- Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine.Frontiers in oncology · 2023Article
- The past, present, and future of immunotherapy for bladder tumors.Medical oncology (Northwood, London, England) · 2022Review
- Establishment of an optimized orthotopic bladder cancer model in mice.BMC urology · 2022Article
- Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity.JCI insight · 2022Article
- The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.Cellular & molecular immunology · 2022Review
- Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation.Frontiers in immunology · 2022Review
- Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.Nature communications · 2021Article
- Immunology of Lynch Syndrome.Current oncology reports · 2021Review
- Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.Aging and disease · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 4 countries.
Funding
Abstract
backgroundWhile significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial) human urothelial carcinoma, also termed non-muscle invasive bladder cancer (NMIBC), remains intractable with bacillus Calmette-Guerin (BCG) employed as the standard of care. In this study, an immunocytokine, NHS-muIL12, which consists of two molecules of murine IL-12 fused to NHS76, a tumor necrosis-targeting human IgG1, was examined as an immunotherapeutic in an orthotopic MB49
methodsThe antitumor activity of systemic administration of NHS-muIL12 was investigated on MB49
resultsStudies revealed a significant reduction in MB49
conclusionsThese findings provide strong evidence that the systemic administration of an immunocytokine consisting of a tumor-targeting Ig through recognition of DNA and DNA-histone complexes coupled to muIL-12 can effectively target the bladder TME; this significantly reduces the myeloid cellular compartment and reverts an immunosuppressive to an immunopermissive TME, ultimately resulting in antitumor effects. These studies provide further rationale for the employment of NHS-IL12 as an immunomodulator and clinical immunotherapeutic for NMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.